2022 World Conference on Lung Cancer (ePosters)-EP05.02-020. IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer

EP05.02-020. IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer

Pdf Summary

The researchers conducted a study to investigate the role of interleukin-9 (IL-9) in lung cancer. They used murine lung carcinoma models and found that IL-9 suppressed the growth of one type of lung cancer cells but not another. Further analysis showed that IL-9 enhanced the anti-tumor T cell response in the responsive tumors. The researchers also investigated the mechanisms by which IL-9 exerted its effects and found that IL-9 increased the expression of MHC-I, which facilitated the infiltration of CD8 T cells into the tumors, leading to tumor suppression.<br /><br />Based on these findings, the researchers suggested that IL-9 could potentially be used in combination with anti-PD-1 therapy to enhance the anti-tumor immune response in lung cancer. The researchers concluded that IL-9 stimulates an anti-tumor immune response and facilitates checkpoint blockade in the mouse model. Further studies are needed to validate these findings in human lung cancer patients.<br /><br />In summary, IL-9 treatment in mice was found to suppress tumor growth and enhance the anti-tumor immune response, specifically the infiltration of CD8 T cells and the increase in MHC-I expression in tumor cells. The combination of IL-9 and anti-PD-1 antibody treatment showed even greater tumor suppression. These findings suggest that IL-9 has potential as a therapeutic target in lung cancer treatment.

Asset Subtitle

Yuqian Feng

Meta Tag

Speaker Yuqian Feng

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

interleukin-9

IL-9

lung cancer

murine lung carcinoma models

tumor suppression

anti-tumor T cell response

MHC-I expression

CD8 T cells

anti-PD-1 therapy

anti-tumor immune response